Tag: rivaroxaban

CASSINI

CASSINI trial results inconclusive on rivaroxaban effects in high-risk ambulatory cancer...

The CASSINI trial found that treatment with rivaroxaban did not significantly reduce the incidence of thromboembolism or death caused by thromboembolism in high-risk ambulatory...

Study proves need for anticoagulant strategy post discharge for hospitalised, at-risk...

Alex C Spyropoulos, from Feinstein Institute for Medical Research (New York, USA), has presented an anticoagulant treatment strategy to reduce non-fatal blood clots and...

Edoxaban emerges as alternative to dalteparin for cancer-associated VTE

A new analysis has identified patient populations with cancer-associated venous thromboembolism (VTE) who could benefit from treatment with oral anticoagulant edoxaban, taken once daily. Daiichi...

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...

Canadian study finds rivaroxaban more effective at preventing recurrent blood clots...

A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of...

Two new real-world studies confirm positive efficacy and safety profile of...

Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...